Signature Biologics Expands Its Irving Footprint With a New Manufacturing and R&D Headquarters

There, Signature Biologics will manufacture perinatal-derived products that improve the body's natural healing processes in wound, musculoskeletal, and pain management applications.

Irving-headquartered Signature Biologics, which manufactures perinatal-derived products that improve the body’s natural healing processes, is growing its operations with a new 36,000-square-foot manufacturing and R&D headquarters.

The newly constructed space, also located in Irving, will feature 16,000 square feet of designated manufacturing laboratory space and 7,500 square feet of R&D space. The company said the design mirrors its transparency in business: The facility has an open floor plan and floor-to-ceiling windows into its manufacturing and R&D laboratories.

Signature Biologics’ new reasearch and development laboratory. [Photo: Signature Biologics]

Signature Biologics plans to keep its current home base as an auxiliary location. There, the team will manage product demands and train future and new employees.

“We’re excited to share this physical progress in our new facility as an outward expression of our dedication and pursuit of excellence in putting biologics to work meeting unmet clinical needs,” Founder and CEO Dr. Riordan said in a statement. “We’ve taken care to make visiting this new facility educational, transparent, and showcase our greatest asset; our brilliant employees who bring our science to the world.”

Inside the new facility

The manufacturing and R&D HQ will support Signature Biologics’ expansion across perinatal derived tissue, acellular products, and cellular products. The company aims to be the “premier, trusted source of innovative perinatal-derived therapeutic solutions.”

Signature Biologics’ manufacturing space. [Photo: Signature Biologics]

Signature Biologics preserves tissue through advanced standardized processing techniques to potentially enhance a body’s natural healing ability in wound, musculoskeletal, and pain management instances. Its process doesn’t alter the structural properties of perinatal tissue, maintaining its integrity for supplementation, reconstruction, repair, or replacement.

Its team uses its decades of experience in biologics to pioneer cellular and acellular products. They see the new facility as filling unmet clinical needs for patients across the globe.

It also includes six manufacturing ISO-7 cleanrooms, 16 ISO-5 manufacturing biosafety cabinets, three R&D cleanrooms, and six research biosafety cabinets.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.
View previous emails.

R E A D   N E X T